Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00635024 · OUTCOME

Number of Participants With Severe Non-hematological Adverse Events

Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma · Source last updated 2017-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
every month during treatment, up to 12 months

What was measured

Severe non-hematologic adverse events were defined as adverse events grade 3 or higher, regardless of attribution to study drug. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE version 3.0)

Groups in this outcome

Anti-thymocyte Globulin/Melphalan

Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Anti-thymocyte Globulin/Melphalan1

Reported measurements

Yes
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Anti-thymocyte Globulin/Melphalan1Not reportedNot reportedNot reportedNot reported
No
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Anti-thymocyte Globulin/Melphalan0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Yes
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    No
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
Severe non-hematologic adverse events were defined as adverse events grade 3 or higher, regardless of attribution to study drug. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE version 3.0)
groups
  1. description
    Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\^2)
    id
    OG000
    title
    Anti-thymocyte Globulin/Melphalan
param Type
NUMBER
reporting Status
POSTED
time Frame
every month during treatment, up to 12 months
title
Number of Participants With Severe Non-hematological Adverse Events
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice